<p><em>州政府資助的篩查倡議凸顯了公共部門對創新癌症檢測工具的日益支持</em></p>
<p>馬里蘭州蓋瑟斯堡，2026 年 3 月 27 日（GLOBE NEWSWIRE）-- 20/20 BioLabs, Inc.（納斯達克：AIDX），一家在基於人工智能的實驗室血液檢測領域早期進入市場的公司，專注於癌症和慢性疾病的早期檢測與預防，今天宣佈，馬里蘭州 18 個消防部門已被通知將共同獲得超過 520,000 美元的資金，用於採購和實施公司的專利_OneTest_™多癌症早期檢測（MCED）血液檢測。</p>
<p>這筆資金來自州政府的 <strong>專業和志願消防員創新癌症篩查技術補助計劃</strong>，由馬里蘭州衞生部（MDH）管理。預計對這些消防員的檢測人數將超過 1,400 人，計劃於今年 4 月或 5 月進行，這代表了通過同一計劃資助的_OneTest_ MCED 數量比去年增加了約 225%。</p>
<p>“索爾茲伯裏消防局對 OneTest 癌症篩查產品非常滿意，” 索爾茲伯裏消防局副局長 Truitt 表示，該局已被通知將再次獲得州政府的資金。“在過去三年中，這些檢測使我們能夠進行近 300 次篩查。通過我們的移動綜合健康團隊和急救人員進行簡單的抽血，我們的成員能夠及時獲得結果，從而進行必要的後續護理。整個過程簡單高效，我們對產品和提供的服務感到非常滿意。”</p>
<p>馬里蘭州是幾個新設立專門補償或補助資金的州之一，以便其消防員能夠獲得 MCED 檢測，預計在未來 24 個月內將有更多州創建類似計劃。根據國家職業安全與健康研究所及其他研究機構的研究，消防員面臨多種癌症類型的職業暴露風險和死亡率較高。</p>
<p>“作為一名曾經的志願消防員，為這個面臨更高癌症暴露風險的社區服務讓我感到特別欣慰，” 20/20 BioLabs 首席執行官 Jonathan Cohen 表示。“我們很自豪能夠通過這些項目支持馬里蘭州的消防部門。我們從這些檢測中獲得的數據，加上我們對全國至少 20,000 名其他消防員的檢測，可以為即將與 FDA 和 CMS 的接觸提供真實的證據，” Cohen 説道。</p>
<p>上個月，國會通過了一項立法並簽署成為法律，為 2028 年開始的醫療保險覆蓋 MCED 建立了一條途徑。公司計劃為其專利的_OneTest_癌症檢測申請醫療保險覆蓋，並相信其將已知蛋白腫瘤標誌物水平與機器學習人工智能結合的專利方法在成本、對許多早期癌症的更好檢測率以及能夠在家中、工作場所或零售地點進行無痛毛細血管血液採集等方面具有顯著優勢。</p>
<p><strong>關於 20/20 BioLabs</strong></p>
<p>20/20 BioLabs, Inc.（納斯達克：AIDX）開發和商業化基於人工智能的實驗室血液檢測，用於癌症和慢性疾病的早期檢測與預防。公司在 OneTest 品牌下提供兩類實驗室檢測。_OneTest™ for Cancer_是一種多癌症早期檢測（MCED）血液檢測，而_OneTest for Longevity™_則測量炎症生物標誌物，預計將在 2026 年上半年推出。OneTest 的經濟實惠、準確、可及的檢測可以方便地在家中使用新的上臂毛細血管採集設備，避免了疼痛的針頭。檢測在其位於馬里蘭州蓋瑟斯堡的美國病理學家學院（CAP）認證、臨牀實驗室改進修正案（CLIA）許可的實驗室中進行。</p>
<p><strong>前瞻性聲明</strong></p>
<p>本公告中的某些聲明屬於《1933 年證券法》第 27A 條和《1934 年證券交易法》第 21E 條所定義的 “前瞻性聲明”。這些前瞻性聲明涉及已知和未知的風險和不確定性，並基於公司對未來事件的當前預期和預測，這些事件可能影響其財務狀況、經營結果、商業戰略和財務需求。前瞻性聲明可以通過 “可能”、“可以”、“將”、“應該”、“會”、“期望”、“計劃”、“打算”、“預期”、“相信”、“估計”、“預測”、“潛在”、“項目”、“繼續” 或這些術語的否定形式或其他類似表達來識別。實際結果可能與這些前瞻性聲明所表達或暗示的結果有重大差異。多種因素可能導致實際結果與這些前瞻性聲明中包含的結果有重大差異，包括但不限於公司在美國證券交易委員會（“SEC”）的文件中描述的風險，這些文件可在 SEC 網站 www.sec.gov 上獲取，包括公司的 S-1 表格註冊聲明（修訂版，文件編號 333-292125），以及我們不時提交或提供的其他報告。公司沒有義務公開更新或修訂任何前瞻性聲明，以反映本公告日期後發生的事件或情況，或反映意外事件的發生，除非適用法律要求。儘管公司相信這些前瞻性聲明中表達的期望是合理的，但無法保證未來結果，投資者應注意實際結果可能與預期結果有重大差異。</p>
<p><strong>投資者關係</strong></p>
<p>克里斯·泰森</p>
<p>MZ 集團</p>
<p>直線電話：949-491-8235</p>
<p>AIDX@mzgroup.us</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RZM09UUTROeU0zTlRBMU1qZzFJekl6TURnNE9EZz0?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="1" height="1" original-src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RZM09UUTROeU0zTlRBMU1qZzFJekl6TURnNE9EZz0"/></p>
<p><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/MGY2NTJmNjEtYTg1NS00MWNjLWFjOWMtYzk5OGE4NTk0NGIzLTEzMjA0MzgtMjAyNi0wMy0yNy1lbg==/tiny/20-20-Biolabs-Inc-.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="1" height="1" original-src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/MGY2NTJmNjEtYTg1NS00MWNjLWFjOWMtYzk5OGE4NTk0NGIzLTEzMjA0MzgtMjAyNi0wMy0yNy1lbg==/tiny/20-20-Biolabs-Inc-.png"/></p>

AIDX

<p>20/20 BioLabs, Inc. 宣佈，18 個馬里蘭州消防部門將從馬里蘭州衞生部門獲得超過 520,000 美元的資金，用於 OneTest™ 多癌症早期檢測血液測試。這項資金是州政府倡議的一部分，旨在對超過 1,400 名消防員進行篩查，比去年增加了 225%。該倡議突顯了對創新癌症檢測工具日益增長的支持，尤其是針對癌症風險較高的消防員。該公司計劃尋求 Medicare 對其測試的覆蓋，這些測試利用人工智能，旨在提高檢測率和成本效益</p>

<p><em>State-Funded Screening Initiative Highlights Growing Public Sector Support for Innovative Cancer Detection Tools</em></p>
<div class="lb-trans"><p><em>州政府資助的篩查倡議凸顯了公共部門對創新癌症檢測工具的日益支持</em></p>
</div><p>GAITHERSBURG, Md., March 27, 2026 (GLOBE NEWSWIRE) -- 20/20 BioLabs, Inc. (Nasdaq: AIDX), an early market entrant in AI powered laboratory-based blood tests for the early detection and prevention of cancers and chronic diseases, today announced that 18 groups of Maryland fire departments have been notified that they will collectively be awarded over $520,000 from the Maryland Department of Health (MDH) to procure and administer the Company’s patented <em>OneTest</em> ™ multi-cancer early detection (MCED) blood test.</p>
<div class="lb-trans"><p>馬里蘭州蓋瑟斯堡，2026 年 3 月 27 日（GLOBE NEWSWIRE）-- 20/20 BioLabs, Inc.（納斯達克：AIDX），一家在基於人工智能的實驗室血液檢測領域早期進入市場的公司，專注於癌症和慢性疾病的早期檢測與預防，今天宣佈，馬里蘭州 18 個消防部門已被通知將共同獲得超過 520,000 美元的資金，用於採購和實施公司的專利_OneTest_™多癌症早期檢測（MCED）血液檢測。</p>
</div><p>The funding is from the state’s <strong>Professional and Volunteer Firefighter Innovative Cancer Screening Technologies Grant Program</strong>, administered by MDH. The testing of these firefighters, estimated to exceed 1,400 individuals, is expected to take place in April or May of this year and represents a ~ 225% increase in the number of <em>OneTest</em> MCEDs funded through the same program last year.</p>
<div class="lb-trans"><p>這筆資金來自州政府的 <strong>專業和志願消防員創新癌症篩查技術補助計劃</strong>，由馬里蘭州衞生部（MDH）管理。預計對這些消防員的檢測人數將超過 1,400 人，計劃於今年 4 月或 5 月進行，這代表了通過同一計劃資助的_OneTest_ MCED 數量比去年增加了約 225%。</p>
</div><p>“The Salisbury Fire Department has been very satisfied with the OneTest cancer screening products,” said Deputy Chief Truitt of the Salisbury MD Fire Department, which was notified that they will again receive funding from the state program. “Over the past three years, these tests have enabled us to carry out almost 300 screenings. With a simple blood draw conducted by our Mobile Integrated Health team and paramedics, our members receive timely results that allow them to pursue any necessary follow-up care. The process has been straightforward and efficient, and we are extremely pleased with both the product and the service provided.”</p>
<div class="lb-trans"><p>“索爾茲伯裏消防局對 OneTest 癌症篩查產品非常滿意，” 索爾茲伯裏消防局副局長 Truitt 表示，該局已被通知將再次獲得州政府的資金。“在過去三年中，這些檢測使我們能夠進行近 300 次篩查。通過我們的移動綜合健康團隊和急救人員進行簡單的抽血，我們的成員能夠及時獲得結果，從而進行必要的後續護理。整個過程簡單高效，我們對產品和提供的服務感到非常滿意。”</p>
</div><p>Maryland is one of several states with newly created, dedicated reimbursement or grant funding for their firefighters to access MCED testing with many more states expected to create such over the next 24 months. Firefighters face higher occupational exposure risk and mortality rates for several different cancer types, according to studies from the National Institute of Occupational Safety and Health and other research groups.</p>
<div class="lb-trans"><p>馬里蘭州是幾個新設立專門補償或補助資金的州之一，以便其消防員能夠獲得 MCED 檢測，預計在未來 24 個月內將有更多州創建類似計劃。根據國家職業安全與健康研究所及其他研究機構的研究，消防員面臨多種癌症類型的職業暴露風險和死亡率較高。</p>
</div><p>“As a former volunteer firefighter, servicing this community at a higher risk for cancer exposure is especially gratifying for me,” noted Jonathan Cohen, Chief Executive Officer of 20/20 BioLabs. “We are proud to support Maryland fire departments through these programs. The data we glean from these tests, coupled with those from at least 20,000 other firefighters from throughout the country that we have tested, can provide real-world evidence to support upcoming engagements with the FDA and CMS,” said Cohen.</p>
<div class="lb-trans"><p>“作為一名曾經的志願消防員，為這個面臨更高癌症暴露風險的社區服務讓我感到特別欣慰，” 20/20 BioLabs 首席執行官 Jonathan Cohen 表示。“我們很自豪能夠通過這些項目支持馬里蘭州的消防部門。我們從這些檢測中獲得的數據，加上我們對全國至少 20,000 名其他消防員的檢測，可以為即將與 FDA 和 CMS 的接觸提供真實的證據，” Cohen 説道。</p>
</div><p>Last month, legislation was passed by Congress and signed into law, establishing a pathway for Medicare coverage of MCEDs beginning in 2028. The Company plans to seek Medicare coverage for its patented <em>OneTest</em> for Cancer, and believes that its patented approach of coupling the levels of well-established protein tumor markers with machine learning AI has considerable advantages over DNA based MCEDs including cost, better detection rates for many earlier stage cancers, and the ability to utilize pain-free capillary blood collection at home, workplaces, or retail locations.</p>
<div class="lb-trans"><p>上個月，國會通過了一項立法並簽署成為法律，為 2028 年開始的醫療保險覆蓋 MCED 建立了一條途徑。公司計劃為其專利的_OneTest_癌症檢測申請醫療保險覆蓋，並相信其將已知蛋白腫瘤標誌物水平與機器學習人工智能結合的專利方法在成本、對許多早期癌症的更好檢測率以及能夠在家中、工作場所或零售地點進行無痛毛細血管血液採集等方面具有顯著優勢。</p>
</div><p><strong>About 20/20 BioLabs</strong></p>
<div class="lb-trans"><p><strong>關於 20/20 BioLabs</strong></p>
</div><p>20/20 BioLabs, Inc. (Nasdaq: AIDX) develops and commercializes AI-powered, laboratory-based blood tests for the early detection and prevention of cancers and chronic diseases. The Company offers two families of lab tests under the OneTest brand. <em>OneTest™ for Cancer</em> is a multi-cancer early detection, or MCED, blood test, and <em>OneTest for Longevity™</em>, which measures inflammatory biomarkers, expected to launch in the first half of 2026. OneTest’s affordable, accurate, accessible tests can be conveniently utilized at home using new, upper arm capillary collection devices that avoid painful needles. Tests are run in its College of American Pathologists (CAP) accredited, Clinical Laboratory Improvement Amendments (CLIA) licensed laboratory in Gaithersburg, MD.</p>
<div class="lb-trans"><p>20/20 BioLabs, Inc.（納斯達克：AIDX）開發和商業化基於人工智能的實驗室血液檢測，用於癌症和慢性疾病的早期檢測與預防。公司在 OneTest 品牌下提供兩類實驗室檢測。_OneTest™ for Cancer_是一種多癌症早期檢測（MCED）血液檢測，而_OneTest for Longevity™_則測量炎症生物標誌物，預計將在 2026 年上半年推出。OneTest 的經濟實惠、準確、可及的檢測可以方便地在家中使用新的上臂毛細血管採集設備，避免了疼痛的針頭。檢測在其位於馬里蘭州蓋瑟斯堡的美國病理學家學院（CAP）認證、臨牀實驗室改進修正案（CLIA）許可的實驗室中進行。</p>
</div><p><strong>Forward-Looking Statements</strong></p>
<div class="lb-trans"><p><strong>前瞻性聲明</strong></p>
</div><p>Certain statements in this release are “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements involve known and unknown risks and uncertainties and are based on the Company’s current expectations and projections about future events that it believes may affect its financial condition, results of operations, business strategy, and financial needs. Forward-looking statements can be identified by words such as “may,” “could,” “will,” “should,” “would,” “expect,” “plan,” “intend,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” “project,” “continue,” or the negative of these terms or other comparable expressions. Actual results may differ materially from those expressed or implied by such forward-looking statements. A number of factors could cause actual results to differ materially from those contained in these forward-looking statements, including, but not limited to, the risks described in the Company’s filings with the U.S. Securities and Exchange Commission (the “SEC”), available on the SEC’s website at www.sec.gov, including the Company’s Registration Statement on Form S-1, as amended (File No. 333-292125), as well as in our other reports filed or furnished from time to time with the SEC. The Company undertakes no obligation to publicly update or revise any forward-looking statements to reflect events or circumstances that occur after the date of this release or to reflect the occurrence of unanticipated events, except as required by applicable law. Although the Company believes the expectations expressed in these forward-looking statements are reasonable, it cannot guarantee future results, and investors are cautioned that actual outcomes may differ materially from those anticipated.</p>
<div class="lb-trans"><p>本公告中的某些聲明屬於《1933 年證券法》第 27A 條和《1934 年證券交易法》第 21E 條所定義的 “前瞻性聲明”。這些前瞻性聲明涉及已知和未知的風險和不確定性，並基於公司對未來事件的當前預期和預測，這些事件可能影響其財務狀況、經營結果、商業戰略和財務需求。前瞻性聲明可以通過 “可能”、“可以”、“將”、“應該”、“會”、“期望”、“計劃”、“打算”、“預期”、“相信”、“估計”、“預測”、“潛在”、“項目”、“繼續” 或這些術語的否定形式或其他類似表達來識別。實際結果可能與這些前瞻性聲明所表達或暗示的結果有重大差異。多種因素可能導致實際結果與這些前瞻性聲明中包含的結果有重大差異，包括但不限於公司在美國證券交易委員會（“SEC”）的文件中描述的風險，這些文件可在 SEC 網站 www.sec.gov 上獲取，包括公司的 S-1 表格註冊聲明（修訂版，文件編號 333-292125），以及我們不時提交或提供的其他報告。公司沒有義務公開更新或修訂任何前瞻性聲明，以反映本公告日期後發生的事件或情況，或反映意外事件的發生，除非適用法律要求。儘管公司相信這些前瞻性聲明中表達的期望是合理的，但無法保證未來結果，投資者應注意實際結果可能與預期結果有重大差異。</p>
</div><p><strong>Investor Relations</strong></p>
<div class="lb-trans"><p><strong>投資者關係</strong></p>
</div><p>Chris Tyson</p>
<div class="lb-trans"><p>克里斯·泰森</p>
</div><p>MZ Group</p>
<div class="lb-trans"><p>MZ 集團</p>
</div><p>Direct: 949-491-8235</p>
<div class="lb-trans"><p>直線電話：949-491-8235</p>
</div><p>AIDX@mzgroup.us</p>
<div class="lb-trans"><p>AIDX@mzgroup.us</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RZM09UUTROeU0zTlRBMU1qZzFJekl6TURnNE9EZz0" alt="" original-src="https://www.globenewswire.com/newsroom/ti?nf=OTY3OTQ4NyM3NTA1Mjg1IzIzMDg4ODg="/></p>
<p><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/MGY2NTJmNjEtYTg1NS00MWNjLWFjOWMtYzk5OGE4NTk0NGIzLTEzMjA0MzgtMjAyNi0wMy0yNy1lbg==/tiny/20-20-Biolabs-Inc-.png" alt="" original-src="https://ml.globenewswire.com/media/MGY2NTJmNjEtYTg1NS00MWNjLWFjOWMtYzk5OGE4NTk0NGIzLTEzMjA0MzgtMjAyNi0wMy0yNy1lbg==/tiny/20-20-Biolabs-Inc-.png"/></p>

Maryland Fire Departments Awarded $520,000 for Cancer Screenings using 20/20 BioLabs’ OneTest ™ Multi-Cancer Early Detection Blood Test | AIDX Stock News

馬里蘭州的消防部門獲得了 52 萬美元的資金，用於使用 20/20 Biolabs 的 OneTest™多癌症早期檢測血液測試進行癌症篩查 | AIDX 股票新聞